Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Arbutus Biopharma CorporationNASDAQ: ABUS

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $179.13M rose 10054.5% year over year, ahead of the +2889.9% change in trailing-twelve-month revenue. Sequentially, it rose 16943.4% from the prior quarter. Over 3 fiscal years it compounded at -28.8% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether revenue reaches the consensus estimate from 1 analysts of $182.2M (+1193.8%) for the fiscal year ending Dec 2026, a step up from the +128.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$179.13M+16943.4% QoQ
Last fiscal yearDec 2025
$14.08M+128.2% YoY
LTMMar 2026
$191.45M+2889.9% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10054.5%-93.5%-10148.0 pp
1 year+128.2%+1193.8%+1065.5 pp
3-year CAGR-28.8%+58.4%+87.2 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
14.08M USD
Year-over-year change
+128.2%
4-year CAGR
+6.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's LTM Mar 2026 revenue of $191.45M is the 3rd highest of the 9 companies compared; the peer median is $67.35M.
  • Its year-over-year change of +2889.9% is the highest of 6, against a peer median of +95.1%.
  • Over three fiscal years its annual growth of -28.8% compares with a peer median of -8.8%.
ABUS Competitors Peer median
Revenue for ABUS and competitors
Company Period LTM YoY 3-year CAGR
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$4.8B +95.1%+53.0%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$450.82M -45.6%+23.3%
ABUSArbutus Biopharma CorporationLTM Mar 2026$191.45M +2889.9%-28.8%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$71.1M +121.1%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$69.21M +7.4%-8.8%
VIRVir Biotechnology, Inc.LTM Mar 2026$65.5M +214.0%-65.1%
SLNSilence Therapeutics plcLTM Mar 2026$921.49K —-68.4%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 ——
BNTCBenitec Biopharma Inc.LTM Mar 2026$0 ——
Peer median (excluding ABUS) $67.35M+95.1%-8.8%

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.99M39.02M18.14M6.17M14.08M
Cost of Revenue0000363K
Gross Profit10.99M39.02M18.14M6.17M13.72M
Gross Margin100.0%100.0%100.0%100.0%97.4%
Research & Development65.5M84.41M73.7M54.04M25.24M
Selling, General & Admin17.14M17.83M22.48M22.11M15.89M
Operating Expenses84.51M104.48M96.24M82.49M40.77M
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
EBITDA(71.64M)(61.86M)(70.99M)(68.4M)(33.04M)
EBITDA Margin-652.0%-158.5%-391.3%-1108.5%-234.6%
Operating Income(73.52M)(65.46M)(78.1M)(76.32M)(27.05M)
Operating Margin-669.1%-167.8%-430.5%-1236.7%-192.1%
Interest Income127K2.19M5.69M6.59M4.07M
Interest Expense2.86M1.73M459K137K97K
Other Income / Expenses(2.73M)444K5.25M6.4M(6.45M)
Income Before Tax(76.25M)(65.01M)(72.85M)(69.92M)(33.5M)
Pre-Tax Margin-693.9%-166.6%-401.6%-1133.0%-237.9%
Income Tax Expense04.44M000
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Net Margin-693.9%-178.0%-401.6%-1133.0%-237.9%
EPS (Basic)(0.73)(0.46)(0.44)(0.38)(0.17)
EPS (Diluted)(0.73)(0.46)(0.44)(0.38)(0.17)
Weighted Avg Shares106.24M150.94M165.96M185.61M191.6M
Weighted Avg Shares (Diluted)106.24M150.94M165.96M185.61M191.6M

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.